{"id":3240,"date":"2025-03-17T16:51:32","date_gmt":"2025-03-17T13:51:32","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=3240"},"modified":"2025-03-17T16:59:56","modified_gmt":"2025-03-17T13:59:56","slug":"capricor-therapeutics-announces-positive-data-demonstrating-long-term-efficacy-of-deramiocel-for-the-treatment-of-duchenne-muscular-dystrophy","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/fr\/capricor-therapeutics-announces-positive-data-demonstrating-long-term-efficacy-of-deramiocel-for-the-treatment-of-duchenne-muscular-dystrophy\/","title":{"rendered":"Capricor Therapeutics annonce des donn\u00e9es positives d\u00e9montrant l&#039;efficacit\u00e9 \u00e0 long terme de Deramiocel pour le traitement de la dystrophie musculaire de Duchenne"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Les r\u00e9sultats positifs \u00e0 long terme de l&#039;essai clinique d&#039;extension en ouvert (\u00ab OLE \u00bb) HOPE-2 en cours de la soci\u00e9t\u00e9 ont \u00e9t\u00e9 annonc\u00e9s aujourd&#039;hui par Capricor Therapeutics, une soci\u00e9t\u00e9 de biotechnologie qui d\u00e9veloppe des th\u00e9rapies transformatrices \u00e0 base de cellules et d&#039;exosomes pour le traitement des maladies rares.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Ces r\u00e9sultats d\u00e9montrent que le principal actif de la soci\u00e9t\u00e9, le deramiocel, a le potentiel de ralentir la progression de la maladie et de pr\u00e9server la fonction des membres sup\u00e9rieurs chez les patients atteints de dystrophie musculaire de Duchenne (\u00ab DMD \u00bb). La conf\u00e9rence clinique et scientifique de la Muscular Dystrophy Association (MSA), qui s&#039;est tenue cette ann\u00e9e \u00e0 Dallas, au Texas, du 16 au 19 mars, a pr\u00e9sent\u00e9 ces donn\u00e9es sous forme d&#039;affiche de derni\u00e8re minute.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Essais cliniques Capricor Therapeutics Deramiocel<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Dans une analyse comparative externe de cohorte appari\u00e9e, l&#039;\u00e9tude a montr\u00e9 que les patients trait\u00e9s par Deramiocel sur trois ans ont connu une baisse moyenne de 3,46 points du score total de Performance du membre sup\u00e9rieur (PUL 2.0), contre 7,19 points dans le groupe comparateur externe (p = 0,019). Cela \u00e9quivaut \u00e0 un ralentissement de la progression de la maladie (% 52), renfor\u00e7ant la durabilit\u00e9 th\u00e9rapeutique potentielle \u00e0 long terme du Deramiocel.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Les r\u00e9sultats suppl\u00e9mentaires comprennent\u00a0:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>L&#039;effet du traitement augmente d&#039;ann\u00e9e en ann\u00e9e<\/strong> \u2013 Les patients sous deramiocel ont montr\u00e9 une r\u00e9duction de la progression de la maladie, avec une baisse annuelle moyenne du PUL 2.0 de 1,8 point la premi\u00e8re ann\u00e9e, de 1,2 point la deuxi\u00e8me ann\u00e9e et de 1,1 point la troisi\u00e8me ann\u00e9e.<\/li>\n\n\n\n<li><strong>Effets potentiels modificateurs de la maladie<\/strong> \u2013 Au cours d\u2019une interruption de traitement d\u2019un an, les patients initialement randomis\u00e9s pour recevoir du deramiocel ont montr\u00e9 un taux de d\u00e9clin plus lent (2,8 points par an) par rapport aux patients non trait\u00e9s (3,7 points par an).<\/li>\n\n\n\n<li><strong>Profil de s\u00e9curit\u00e9 favorable<\/strong> \u2013 Le Deramiocel a \u00e9t\u00e9 bien tol\u00e9r\u00e9, aucun nouveau signal de s\u00e9curit\u00e9 n\u2019a \u00e9t\u00e9 identifi\u00e9 et continue de maintenir un profil b\u00e9n\u00e9fice-risque \u00e0 long terme favorable.<\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>Positive long-term results from the company&#8217;s ongoing HOPE-2 open label extension (&#8220;OLE&#8221;) clinical trial were announced today by Capricor Therapeutics, a biotechnology company that develops transformative cell and exosome-based therapeutics for the treatment of rare diseases. These results show that the company&#8217;s lead asset, deramiocel, has the potential to slow the progression of the disease [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3241,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[90,87,89,85,301,297],"class_list":["post-3240","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-cap-1002","tag-capricor-therapeutics","tag-cardiomyopathy","tag-deramiocel","tag-hope-2","tag-muscular-dystrophy-association"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts\/3240","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/comments?post=3240"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts\/3240\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/media\/3241"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/media?parent=3240"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/categories?post=3240"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/tags?post=3240"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}